IL143295A0 - New cancer treatments - Google Patents
New cancer treatmentsInfo
- Publication number
- IL143295A0 IL143295A0 IL14329599A IL14329599A IL143295A0 IL 143295 A0 IL143295 A0 IL 143295A0 IL 14329599 A IL14329599 A IL 14329599A IL 14329599 A IL14329599 A IL 14329599A IL 143295 A0 IL143295 A0 IL 143295A0
- Authority
- IL
- Israel
- Prior art keywords
- cell lines
- prostate cancer
- heterogeneity
- cancer treatments
- new cancer
- Prior art date
Links
- 201000011510 cancer Diseases 0.000 title abstract 2
- 238000011282 treatment Methods 0.000 title abstract 2
- 206010028980 Neoplasm Diseases 0.000 title 1
- 206010060862 Prostate cancer Diseases 0.000 abstract 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 abstract 2
- 230000000735 allogeneic effect Effects 0.000 abstract 1
- 230000000890 antigenic effect Effects 0.000 abstract 1
- 238000001574 biopsy Methods 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 230000001024 immunotherapeutic effect Effects 0.000 abstract 1
- 238000009169 immunotherapy Methods 0.000 abstract 1
- 208000010658 metastatic prostate carcinoma Diseases 0.000 abstract 1
- 230000010076 replication Effects 0.000 abstract 1
- 229960005486 vaccine Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/22—Urine; Urinary tract, e.g. kidney or bladder; Intraglomerular mesangial cells; Renal mesenchymal cells; Adrenal gland
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5152—Tumor cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/80—Vaccine for a specifically defined cancer
- A61K2039/884—Vaccine for a specifically defined cancer prostate
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Oncology (AREA)
- Microbiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Cell Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Developmental Biology & Embryology (AREA)
- Virology (AREA)
- Zoology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB9827103.4A GB9827103D0 (en) | 1998-12-10 | 1998-12-10 | New cancer treatments |
| PCT/GB1999/004135 WO2000033870A2 (en) | 1998-12-10 | 1999-12-09 | New cancer treatments |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL143295A0 true IL143295A0 (en) | 2002-04-21 |
Family
ID=10843925
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL14329599A IL143295A0 (en) | 1998-12-10 | 1999-12-09 | New cancer treatments |
| IL143295A IL143295A (en) | 1998-12-10 | 2001-05-22 | Immunological substances and preparations containing them for the treatment of cancer |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL143295A IL143295A (en) | 1998-12-10 | 2001-05-22 | Immunological substances and preparations containing them for the treatment of cancer |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US6699483B1 (https=) |
| EP (1) | EP1137434B1 (https=) |
| JP (1) | JP4607330B2 (https=) |
| KR (1) | KR100612552B1 (https=) |
| AT (1) | ATE412425T1 (https=) |
| AU (1) | AU777969B2 (https=) |
| CA (1) | CA2354046C (https=) |
| CZ (1) | CZ20012033A3 (https=) |
| DE (1) | DE69939837D1 (https=) |
| ES (1) | ES2315024T3 (https=) |
| GB (1) | GB9827103D0 (https=) |
| HU (1) | HUP0104857A3 (https=) |
| IL (2) | IL143295A0 (https=) |
| MX (1) | MXPA01005815A (https=) |
| NO (1) | NO326035B1 (https=) |
| NZ (1) | NZ512005A (https=) |
| PL (1) | PL348829A1 (https=) |
| WO (1) | WO2000033870A2 (https=) |
| ZA (1) | ZA200104163B (https=) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE60144515D1 (de) * | 2000-04-01 | 2011-06-09 | Onyvax Ltd | Prostata zellinien und deren verwendung |
| AU2002232560A1 (en) | 2000-10-27 | 2002-05-06 | Immuno-Rx, Inc | Vaccine immunotherapy for immune suppressed patients |
| US20070025958A1 (en) | 2000-10-27 | 2007-02-01 | Hadden John W | Vaccine immunotherapy |
| CA2476999C (en) * | 2002-02-22 | 2015-09-15 | Intracel Resources Llc | Sterile immunogenic non-tumorigenic tumor cell compositions and methods |
| US7176022B2 (en) * | 2002-12-20 | 2007-02-13 | Cell Genesys, Inc. | Directly injectable formulations which provide enhanced cryoprotection of cell products |
| US20050019336A1 (en) | 2003-07-23 | 2005-01-27 | Dalgleish Angus George | Human prostate cell lines in cancer treatment |
| US20050180952A1 (en) * | 2003-08-26 | 2005-08-18 | Pettis Ronald J. | Methods for intradermal delivery of therapeutics agents |
| EP2591786B1 (en) | 2003-10-16 | 2017-04-12 | Cancure Limited | Immunomodulating compositions and uses therefor |
| US8257715B1 (en) * | 2004-08-26 | 2012-09-04 | University Of Notre Dame | Tissue vaccines and uses thereof |
| US20090196850A1 (en) | 2005-01-06 | 2009-08-06 | Novo Nordisk A/S | Anti-Kir Combination Treatments and Methods |
| US9308252B2 (en) * | 2005-10-27 | 2016-04-12 | Cook Biotech, Inc. | Extracellular matrix materials as vaccine adjuvants for diseases associated with infectious pathogens or toxins |
| US8802113B2 (en) * | 2005-10-27 | 2014-08-12 | University Of Notre Dame | Extracellular matrix cancer vaccine adjuvant |
| US8778362B2 (en) | 2005-10-27 | 2014-07-15 | University Of Notre Dame | Anti-tumor/cancer heterologous acellular collagenous preparations and uses thereof |
| US8778360B2 (en) * | 2005-10-27 | 2014-07-15 | University Of Notre Dame | Extracellular matrix cancer vaccine adjuvant |
| GB0601598D0 (en) * | 2006-01-26 | 2006-03-08 | Stathopoulos Apostolos | Method |
| US9283266B2 (en) * | 2008-02-28 | 2016-03-15 | University Of Notre Dame | Metastasis inhibition preparations and methods |
| US20110250218A1 (en) | 2008-10-29 | 2011-10-13 | Fong Lawrence H | Disease-Associated Antigens and Methods of Use Thereof |
| CA3017298C (en) | 2009-05-15 | 2021-09-28 | Irx Therapeutics, Inc. | Compositions comprising primary cell-derived biologics for enhancing immune responses in patients |
| US8846059B2 (en) | 2009-12-08 | 2014-09-30 | University Of Notre Dame | Extracellular matrix adjuvant and methods for prevention and/or inhibition of ovarian tumors and ovarian cancer |
| ES2667476T3 (es) | 2009-12-08 | 2018-05-11 | Irx Therapeutics, Inc. | Método para invertir la supresión inmunitaria de células de Langerhans |
| US20110150934A1 (en) * | 2009-12-18 | 2011-06-23 | University Of Notre Dame | Ovarian Tumor Tissue Cell Preparations/Vaccines for the Treatment/Inhibition of Ovarian Tumors and Ovarian Cancer |
| CN105850982B (zh) * | 2016-04-29 | 2018-08-17 | 绍兴市人民医院 | 一种新型组织冻存液 |
| CN105850981B (zh) * | 2016-04-29 | 2018-07-20 | 绍兴市人民医院 | 冻存肿瘤组织的方法 |
| CN114729324A (zh) * | 2019-07-24 | 2022-07-08 | 斯比根公司 | 永生化干细胞株的制备方法及其用途 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5788963A (en) * | 1995-07-31 | 1998-08-04 | Pacific Northwest Cancer Foundation | Isolation and/or preservation of dendritic cells for prostate cancer immunotherapy |
| JP2000502711A (ja) * | 1995-12-28 | 2000-03-07 | ザ ジョンズ ホプキンズ ユニヴァーシティ スクール オブ メディシン | 同種異系パラクリンサイトカイン腫瘍ワクチン |
| WO1997028255A1 (en) * | 1996-02-02 | 1997-08-07 | The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services | Immortal human prostate epithelial cell lines and clones and their applications in the research and therapy of prostate cancer |
| EP1125133A1 (en) * | 1998-11-03 | 2001-08-22 | Cell Genesys, Inc. | Novel cancer-associated antigens and methods of their identification |
| GB9827104D0 (en) * | 1998-12-10 | 1999-02-03 | Onyvax Ltd | New cancer treatments |
-
1998
- 1998-12-10 GB GBGB9827103.4A patent/GB9827103D0/en not_active Ceased
-
1999
- 1999-12-09 NZ NZ512005A patent/NZ512005A/xx unknown
- 1999-12-09 AU AU16687/00A patent/AU777969B2/en not_active Ceased
- 1999-12-09 JP JP2000586360A patent/JP4607330B2/ja not_active Expired - Fee Related
- 1999-12-09 AT AT99959548T patent/ATE412425T1/de not_active IP Right Cessation
- 1999-12-09 CZ CZ20012033A patent/CZ20012033A3/cs unknown
- 1999-12-09 KR KR1020017007095A patent/KR100612552B1/ko not_active Expired - Fee Related
- 1999-12-09 HU HU0104857A patent/HUP0104857A3/hu unknown
- 1999-12-09 US US09/857,690 patent/US6699483B1/en not_active Expired - Lifetime
- 1999-12-09 EP EP99959548A patent/EP1137434B1/en not_active Expired - Lifetime
- 1999-12-09 ES ES99959548T patent/ES2315024T3/es not_active Expired - Lifetime
- 1999-12-09 WO PCT/GB1999/004135 patent/WO2000033870A2/en not_active Ceased
- 1999-12-09 CA CA2354046A patent/CA2354046C/en not_active Expired - Fee Related
- 1999-12-09 MX MXPA01005815A patent/MXPA01005815A/es active IP Right Grant
- 1999-12-09 DE DE69939837T patent/DE69939837D1/de not_active Expired - Lifetime
- 1999-12-09 IL IL14329599A patent/IL143295A0/xx active IP Right Grant
- 1999-12-09 PL PL99348829A patent/PL348829A1/xx unknown
-
2001
- 2001-05-22 IL IL143295A patent/IL143295A/en not_active IP Right Cessation
- 2001-05-22 ZA ZA200104163A patent/ZA200104163B/en unknown
- 2001-06-07 NO NO20012818A patent/NO326035B1/no not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| KR20010090873A (ko) | 2001-10-19 |
| AU777969B2 (en) | 2004-11-04 |
| ZA200104163B (en) | 2002-02-04 |
| NO20012818L (no) | 2001-06-07 |
| CA2354046A1 (en) | 2000-06-15 |
| EP1137434B1 (en) | 2008-10-29 |
| JP2002531521A (ja) | 2002-09-24 |
| AU1668700A (en) | 2000-06-26 |
| IL143295A (en) | 2006-04-10 |
| WO2000033870A2 (en) | 2000-06-15 |
| KR100612552B1 (ko) | 2006-08-11 |
| NO326035B1 (no) | 2008-09-01 |
| HUP0104857A2 (hu) | 2002-04-29 |
| NZ512005A (en) | 2004-01-30 |
| ES2315024T3 (es) | 2009-03-16 |
| GB9827103D0 (en) | 1999-02-03 |
| MXPA01005815A (es) | 2003-04-02 |
| CZ20012033A3 (cs) | 2001-10-17 |
| CA2354046C (en) | 2011-02-15 |
| ATE412425T1 (de) | 2008-11-15 |
| WO2000033870A3 (en) | 2000-08-17 |
| PL348829A1 (en) | 2002-06-17 |
| NO20012818D0 (no) | 2001-06-07 |
| DE69939837D1 (de) | 2008-12-11 |
| JP4607330B2 (ja) | 2011-01-05 |
| HUP0104857A3 (en) | 2004-04-28 |
| US6699483B1 (en) | 2004-03-02 |
| EP1137434A2 (en) | 2001-10-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL143295A0 (en) | New cancer treatments | |
| WO2004113571A3 (en) | Prostate specific genes and the use thereof as targets for prostate cancer therapy and diagnosis | |
| JP2006525995A5 (https=) | ||
| DE69534946D1 (de) | Verwendung von nackten Polynukleotiden zur Herstellung eines Medikaments für die Behandlung von Tumoren | |
| AU2003302892A8 (en) | Compositions and methods for the therapy and diagnosis of prostate cancer | |
| IL231810A (en) | History of itensinoid and pharmaceutical preparations containing the same methods of preparation and use thereof for cancer treatment | |
| IL184617A0 (en) | Dr5 antibodies and uses thereof | |
| HUP0203968A2 (hu) | Készítmények és eljárások prosztatarák terápiájára és diagnózisára | |
| WO2004112825A3 (en) | Combinations of tumor-associated antigens for the treatment of various types of cancers | |
| WO2003097835A3 (en) | Pharmaceutical compositions for the treatment of cancer | |
| WO2007147128A3 (en) | Non-toxic anti-cancer drug combining ascorbate, magnesium and a naphthoquinone | |
| TW200612988A (en) | Adjuvant therapy with the use of anti-glypican 3 antibody | |
| Naylor et al. | Treatment of advanced melanoma with laser immunotherapy and ipilimumab | |
| Nikolsky | Break in the cosmic ray spectrum or confinement violation near 10 6 TeV? | |
| BRPI0612334A2 (pt) | uso de uma abordagem baseada em galectina-1 direcionada para rnai no tratamento do cÂncer | |
| WO2000033869A3 (en) | Use of human prostrate cell lines in cancer treatment | |
| IL114382A (en) | Lymphotoxin for use as a medicament for cancer therapy and use thereof in the manufacture of such medicament | |
| WO2011056566A3 (en) | Compounds and methods for treatment of cancer | |
| WO2000033871A3 (en) | Use of human prostate tumour cell lines in cancer treatment | |
| WO2005051990A3 (en) | Polynucleotides overexpressed in breast cancer cells, compositions and methods for the therapy and diagnosis of breast cancer | |
| Yang et al. | Effect of chronic endogenous antigen stimulation on CAR T cell persistence and memory formation | |
| WO2004015063A3 (en) | Amplification and overexpression of oncogenes | |
| GB2419530A (en) | Human prostate cell lines in cancer treatment | |
| Kerr | A United Kingdom coordinating committee on cancer research study of adjuvant chemotherapy for colorectal cancer: preliminary results | |
| AU2002228940A1 (en) | Compositions and methods for the therapy and diagnosis of lung cancer |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FF | Patent granted | ||
| KB | Patent renewed |